1. At a Glance – Smallcap With a Big Surname and Bigger Mood Swings
₹209 crore market cap.
₹27.3 stock price.
Down 39% in one year.
Down 11% in three months.
Yet Q3 FY26 profit up 93.7% YoY.
Ladies and gentlemen, welcome to Ambalal Sarabhai Enterprises Ltd — where pharmaceuticals meet electronics, and volatility meets legacy.
This is a company with:
- Stock P/E: 11.8
- Book value: ₹19.2
- Price to book: 1.42
- ROE: 6.25%
- ROCE: 9.12%
- Debt to equity: 0.32
- Enterprise value: ₹243 crore
- EV/EBITDA: 9.49
Latest quarter (Q3 FY26) numbers:
- Sales: ₹52 crore
- PAT: ₹3.64 crore
- EPS: ₹0.47
And yes — earnings jumped nearly 94% YoY.
But here’s the question:
Is this a sleeping legacy pharma-electronics hybrid?
Or is it just another smallcap that occasionally remembers it’s profitable?
Let’s dissect this like a molecular diagnostics lab.
2. Introduction – The Sarabhai Legacy Meets Smallcap Reality
The Sarabhai name is not some random surname.
It’s a legacy industrial family. Big in science. Big in business. Big in reputation.
But Ambalal Sarabhai Enterprises today is not the blue-blood giant you imagine.
It’s a ₹209 crore smallcap juggling:
- Pharmaceuticals
- Fermentation APIs
- Oncology products
- Diagnostics JVs
- Electronics instruments
- And even broadcast equipment distribution
This is not a pure-play pharma company.
It’s more like a diversified thali.
Pharma contributes around 60% of segment revenue.
Electronics contributes about 40%.
So you’re buying into:
- USFDA-inspected fermentation business
- Oncology API plant
- Molecular diagnostics JV
- Analytical instrument manufacturing
- Sony broadcast equipment representation via Telerad
That’s a lot for ₹209 crore market cap.
But if it’s so diversified and so “legacy,” why is ROE just 6%?
Why is promoter holding only 31.4%?
Why has sales grown only 8% CAGR over five years?
Let’s go deeper.
3. Business Model – WTF Do They Even Do?
Imagine a company meeting:
“Sir, what business are we in?”
“Yes.”
That’s Ambalal Sarabhai.
Pharma Segment (60%)
Through subsidiaries like:
- Asence Pharma
- Synbiotics (USFDA inspected)
- Sarabhai Chemicals
- Suvik Hitek
- Sarabhai M Chemicals
They manufacture:
- Fermentation APIs
- Synthetic bulk drugs
- Effervescent products
- Oncology APIs
- Vitamin C coated products
- Amphotericin B antifungal API
They even completed a demerger of oncology division into Asence Pharma.
So pharma side is serious.
Electronics Segment (40%)
Through Systronics and Telerad:
- Analytical & measuring instruments
- Broadcast & professional video equipment
- Recently launched
